CERKL notes

2026-10-10 substantive annotation review

CERKL has 16 original annotations and eight alternative products. This review preserves every original source object, including the two PPM1A partners, electronic donors and PAINT nodes. One new molecular-function annotation records direct mRNA binding by the sequence-defined human CERKLa product. No new biological-process or NOT assertion is introduced.

The campaign's immutable curation instructions permit supported generic binding to remain non-core where no stronger MF is justified. Here both original PPM1A associations admit a partner-class refinement; neither is interpreted as CERKL phosphatase activity or activation. The ancestry/comparator restriction for new process terms is not extended into a categorical ban on new molecular functions.

Own molecular activities and product boundaries

PMID:24498393(https://doi.org/10.1371/journal.pone.0087898), Figure 4C-D and its protein-purification/RNA-EMSA Methods, directly tests bacterial His-MBP-tagged human CERKLa. Purified protein shifts mRNA from human retina or COS-7 cells with protein-negative and unlabeled-competition controls. The N-terminal 1–256 fragment retains binding; the 252–532 fragment does not. The paper's NM_201548.4 translation, NP_963842.1, exactly matches the 532-aa current Q49MI3-2 sequence after the documented VSP_016659 deletion from displayed Q49MI3-1. This is tested-product specificity, not proof that other products lack the function. Short exact source anchors are present in the NEW annotation and RNA-binding core.

The same paper's cap-affinity experiment uses a human-cell immunoprecipitate, so it does not establish purified direct cap recognition. Its microtubule and translation-factor associations also include complex/RNA-mediated interactions. No direct microtubule-binding, translation-factor, motor or RNA-transport activity is added. The cellular mRNP evidence supplies context for mRNA binding without proving that RNA binding causes protection from apoptosis.

PMID:23501591(https://doi.org/10.1016/j.exer.2013.03.003), Sections 2.6–2.8 and Figure 8, reports sphingomyelin, glucosylceramide and galactosylceramide association using transfected HEK293T protein lysates and immobilized lipids. Retinoic-acid signal also occurred with empty vector and was discarded. This is not a purified affinity or transport assay. Earlier PMID:19158957(https://pmc.ncbi.nlm.nih.gov/articles/PMC2628313/), Results following Figure 3, reported negative overlays with both purified GST-CERKLa and fresh HEK293T lysate. The retained sphingolipid-binding annotation is therefore bounded to the positive assay context, not a universal behavior or explanation of all retinal lipid phenotypes. The 2013 mouse model retained about 35% expression and should not be described as a complete null.

Why the catalytic transfers are rejected

The kinase name/domain alone does not establish phosphorylation. Full selected Methods and Results of PMID:19158957 test four cloned human retinal a/b/c/d products, both cell lysates and purified GST formats, with functioning CERK controls, standard and photoreceptor-derived lipid preparations, and cellular labeling. PMID:23501591 extends the negative tests to very-long-chain ceramides and mixed-lipid phosphorus assays. PMID:22678504(https://pmc.ncbi.nlm.nih.gov/articles/PMC3394741/) provides additional C6-NBD-ceramide/CERK-control assay text, although its exact full-length construct mapping remains limited.

These are target-specific reasons to reject positive lipid-kinase and kinase inferences. They do not prove inactivity of all eight products under every substrate/cofactor condition. No NOT annotation is manufactured. The current InterPro IPR001206 record really does map to GO:0016301: the issue is transfer to this target, not a nonexistent mapping or fabricated lost residue. Historical PAINT node PTN002285910 remains explicitly unresolved; donor count and target self-evidence are not used as objections.

Survival and context-dependent regulation

PMID:19158957 Figure 7 measures PARP cleavage in human HeLa cells expressing human 532-aa CERKLa. Protection is seen with 300 micromolar hydrogen peroxide over 12–24 hours, with important negative boundaries at the higher dose, other stimuli and later time point. The COS-7 propidium-iodide experiment separately measures both necrotic and apoptotic death. The existing negative-apoptosis BP is retained, without inventing intrinsic antioxidant or caspase-inhibitor molecular activity.

The authentic abstract of PMID:24735978(https://doi.org/10.1016/j.bbadis.2014.04.009) reports TRX2 association, redox-state maintenance and protection; its full Methods were not recovered, so biochemical species/product assignments and direct redox catalysis are not inferred. PMID:30205735(https://doi.org/10.1080/15548627.2018.1520548), Figures 5–9 and the cloning/RNAi Methods, supports CERKL-dependent SIRT1 stability and autophagy in human ARPE-19 cells through depletion/rescue and tagged co-IP. It does not show CERKL deacetylase or kinase activity.

The newer PMID:41288005(https://pubmed.ncbi.nlm.nih.gov/41288005/), Results 3.6–3.7 and the lipid/PI3P/LC3 Methods, instead finds lower PI3P and autophagy with CERKL expression in human pancreatic cancer lines, including bafilomycin controls. Its Discussion explicitly distinguishes the ARPE-19 result. No universal autophagy direction, new cancer process or direct lipid-catalytic activity is asserted. Product identity in these two autophagy papers remains incompletely resolved.

Localization and exact source tracing

The mouse donor A2AQH1 has exact IDA segment-localization records from PMID:23142158(https://pubmed.ncbi.nlm.nih.gov/23142158/). Its Figure 3 and immunofluorescence Methods show mouse and rat inner/outer-segment labeling with omitted-primary controls. Those are ortholog observations, not direct human-segment experiments.

PMID:21151604(https://pubmed.ncbi.nlm.nih.gov/21151604/), Figures 4–6 and antibody Methods, directly shows endogenous human ARPE-19 nuclear, cytoplasmic and perinuclear CERKL, with antigen-pre-absorption controls. It also finds exclusion from fibrillarin-positive nucleoli in human ARPE-19 and mouse 661W cells. This differs from expressed-product nucleolar accumulation seen by two independent groups in PMID:19158957 and PMID:19501188. The nucleolus assertion is retained as a non-core expression-context observation; its physiological relevance remains a question. In contrast, the ER and Golgi electronic locations are over-annotations: the 2009 imaging/fractionation is overexpressed and non-exclusive, and the later PMID:24498393 Figure S1 reports no colocalization with those organelle markers. No uniform localization of all eight products is claimed.

Interaction evidence and access provenance

CERKL-source-evidence.json contains literal source objects, exact interaction records, donor annotations, source URLs/query receipts and SHA-256 hashes. It is a curated source extract, not a custom sequence-analysis pipeline or a claim that every full supplement was inspected.

For PMID:33961781(https://doi.org/10.1016/j.cell.2021.04.011), three exact IntAct records link Q49MI3 to P35813 in human HEK293T/HCT116 AP-MS experiments. For PMID:40205054(https://doi.org/10.1038/s41586-025-08878-3), the publication-linked author AP-MS network contains CERKL–PPM1A edge 609146. UniProt independently establishes P35813 as PPM1A, a protein Ser/Thr phosphatase. These observations support protein phosphatase binding at physical-association resolution; they do not establish a purified binary interface, activation, substrate or individual CERKL product. Database records and GOA share source provenance; repeated records are not automatically biological replication.

The genuine normal seed and source caches were preserved. Existing main caches were selected exactly; missing references were obtained by the unchanged normal fetch command in isolation. Falcon was attempted with a 90-second bound and timed out; the explicit Perplexity-lite fallback returned HTTP 401 for insufficient quota. No provider report was fabricated. Manual primary research continued. The normal abstracts of PMID:15708351, PMID:19501188 and PMID:24735978 remain explicitly abstract-only; selected complete primary papers carry the actual load-bearing claims.

Independent annotation-review and core-synthesis consultations assessed catalytic transfer and positive mRNA binding separately. GO definitions were checked through the official service. The authenticated GO-CAM index had no CERKL/Q49MI3 entry. This absence was not used to manufacture a new process. All newly authored source excerpts, including repeats, are counted per publication; notes introduce no additional verbatim literature excerpts.

2026-10-10 source-specific follow-up to PR #4531

This dated entry supersedes only the ER/Golgi over-annotation interpretation in the preceding localization paragraph. The entire notes file at head 478d1237f73e3e33e5c103bd2a4d8584bbb5b30c is retained as an exact prefix. That head incorporated an intervening localization change after 447d901981a2015ff392eeeda0e27e09ecbd9fb2; its independent nucleolar citation and apoptosis dose/time clarification remain valid. The current source objects and all eight product records remain unchanged.

The full PMID:19158957(https://pmc.ncbi.nlm.nih.gov/articles/PMC2628313/) localization Results and Figure 4E explicitly report calnexin and GM130 overlap for expressed human retinal products in COS-7 cells. The subsequent negative comparison concerns endosomal and mitochondrial markers. Figure 5 and its sucrose-gradient Methods separately place human HeLa CERKLa-HA in ER/Golgi marker fractions, with stronger trans-Golgi/Golgi overlap. These positive observations support conditional association with both compartments; distribution over several compartments is not evidence against either individual location. They do not demonstrate endogenous retinal residence, exclusive compartment identity or membrane topology. The later PMID:24498393(https://doi.org/10.1371/journal.pone.0087898) Results/Figure S1 locate aggregates partly around the ER and find no corresponding ER/Golgi marker colocalization. Accordingly both source locations are retained as non-core with these differing expression contexts explicit, not as universal steady-state locations.

The independent PMID:19501188(https://pubmed.ncbi.nlm.nih.gov/19501188/) abstract corroborates expressed CERKL nucleolar accumulation. Only the authentic abstract was recovered, so its host, construct and product mapping remain unassigned. Together with the positive tagged-product assay in PMID:19158957, this contrasts with endogenous ARPE-19 and 661W nucleolar exclusion in PMID:21151604(https://pubmed.ncbi.nlm.nih.gov/21151604/). The two positive reports are retained without conflating overexpression and endogenous distributions.

The PPM1A refinements remain at AP-MS complex-association resolution: two of the three BioPlex records are spoke-expanded, and the U2OS network is another AP-MS context. No separate low-throughput orthogonal binary assay was verified. The original machine records remain literal in CERKL-source-evidence.json; no phosphatase activation, substrate assignment or intrinsic CERKL catalysis is inferred.

For sphingolipid binding, PMID:23501591(https://pubmed.ncbi.nlm.nih.gov/23501591/) Figure 8 actually uses human CERKLa-containing HEK293T lysate, despite the retained mouse-donor IEA. Positive sphingomyelin and monohexosylceramides are distinguished from negative ceramide, lactosylceramide, GM1 and free fatty acids; retinoic-acid signal was also present with empty-vector lysate. A curator question records the human-source opportunity without fabricating a source annotation or a purified binary interaction. The survival core preserves the intervening clarification of 300 micromolar hydrogen peroxide over 12–24 hours; the annotation reason retains the stronger-dose, later-time and other-stimulus limitations. No additional core activity or process annotation is proposed.

2026-11-05 ORGANELLES ER batch 2 (endoplasmic reticulum rows)

Row: GO:0005783 IEA (GO_REF:0000044, SL-0095), KEEP_AS_NON_CORE (unchanged).

Checks:
- UniProt location for the displayed isoform is "Cytoplasm. Nucleus, nucleolus."; ER appears only in "[Isoform 2]: Cytoplasm. Nucleus, nucleolus. Golgi apparatus, trans-Golgi network. Endoplasmic reticulum." with no evidence tag [file:human/CERKL/CERKL-uniprot.txt].
- PMID:19158957 (full text) tested several isoforms: "neither a unique localization pattern nor a restricted subcellular localization could be ascribed to any CERKL isoform"; Figure 4E calnexin overlap in transfected cells ("mainly ER and Golgi"); HA-tagged CERKLa in PDI-containing sucrose fractions that also carry Golgi markers. So the isoform-2 restriction is UniProt's, and no source_defects entry was recorded.
- No signal peptide, TM or retention motif; all ER data are on overexpressed tagged constructs; PMID:24498393 sees aggregates partly around the ER without marker colocalization.

Outcome: KEEP_AS_NON_CORE kept (precedent AHCY, ER batch 1), with a dated ORGANELLES sentence; close call with MARK_AS_OVER_ANNOTATED stated in the reason. No sub-compartment (cytosolic-face pool).